https://doi.org/10.4081/ejtm.2024.12939

Evaluation relationship between VDR gene and clinical and inflammatory factors in patients with RRMS

Early Access
Submitted: 18 August 2024
Accepted: 2 September 2024
Published: 9 October 2024
Vitamin D receptor, gene changes, clinical and inflammatory factors, relapsing-remitting multiple sclerosis
Abstract Views: 0
PDF: 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Maryam Milanifard
Department of Anatomy, School of Medicine, Iran university of Medical Sciences, Tehran, Iran, Islamic Republic of.
Soraya Mehrabi
Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Reza Ahadi
Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Mohsen Nabiuni
Assistant Professor of Neurosurgery, Spine Fellowship, Faculty member, Department of Neurosurgery, Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Samaneh Azimi Souteh
Department of Radiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Mohammad Taghi Joghataei
m_joghataei@yahoo.com
Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran; Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of.

Introduction: Adipocyte levels including leptin and FABS-4 levels, adiponectin, obesity, and vitamin D can be related to the occurrence and exacerbation of MS disease.

Objective: This research aimed at determining the relationship between VDR gene changes and clinical and inflammatory factors in patients with relapsing-remitting multiple sclerosis (RRMS).

Method: This case/control study was conducted based on the ethical principles of Helsinki. RRMS disease was confirmed based on history, clinical signs, radiological signs, and neurologist's diagnosis. The research population consisted of healthy people and patients with RRMS referring to Hazrat Rasool Akram Hospital between 2021 and 2023 who met the criteria for entering the research.

Results: FokI polymorphism is associated with a substantial increase in risk, with an odds ratio of 7.28, for those with the FF genotype who have RRMS compared to healthy individuals (OR=7.28: 95% CI; 1.86, 28.41). The presence of FokI polymorphism significantly raises the likelihood of developing RRMS in persons with the FF genotype compared to healthy individuals, with an odds ratio of 28.7. RRMS patients with genotypes did not exhibit a significant increase in risk compared to controls for FokI, ApaI, TaqI, and BsmI polymorphisms.

Conclusion: None of the studied polymorphisms revealed a significant risk in obese patients with different genotypes compared to the obese people. Further research, including more cases, is needed to avoid results that could be inflated by small samples or low frequencies of minor alleles.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Plaudit

Pegoretti V, Swanson KA, Bethea JR, et al. Inflammation and oxidative stress in multiple sclerosis: consequences for therapy development. Oxidative Med Cell Longev 2020;2020:7191080.
Tobore TO. Oxidative/nitroxidative stress and multiple sclerosis. J Mol Neurosci 2021;71:506-14.
Adamczyk B, Adamczyk-Sowa M. New insights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis. Oxidative Med Cell Longev 2016;2016:1973834.
Lee D-H, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Molec Sci 2012;13:11783-803.
Schreiner T-G, Genes T-M. Obesity and multiple sclerosis—A multifaceted association. J Clin Med 2021;10:2689.
Correale J, Marrodan M. Multiple sclerosis and obesity: The role of adipokines. Front Immunol 2022;13:1038393.
Pantazou V, Schluep M, Du Pasquier R. Environmental factors in multiple sclerosis. La Presse Médicale 2015;44:e113-e20.
Agliardi C, Guerini FR, Saresella M, et al. Vitamin D receptor (VDR) gene SNPs influence VDR expression and modulate protection from multiple sclerosis in HLA-DRB1* 15-positive individuals. Brain Behav Immun 2011;25:1460-7.
Pierrot-Deseilligny C, Souberbielle J-C. Vitamin D and multiple sclerosis: An update. Multiple Sclerosis Rel Disord 2017;14:35-45.
Mohammadi A, Azarnezhad A, Khanbabaei H, et al. Vitamin D receptor genetic polymorphisms and the risk of multiple sclerosis: A systematic review and meta-analysis. Steroids 2020;158:108615.
Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Therapy 2018;7:59-85.
Holick MF, editor High prevalence of vitamin D inadequacy and implications for health. Mayo Clinic Proceedings; 2006: Elsevier.
Goodyear MD, Krleza-Jeric K, Lemmens T. The declaration of Helsinki. BMJ 2007;335:624-5.
Lee DH, Peschke M, Utz K, Linker R. Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing–remitting multiple sclerosis. Eur J Neurol 2019;26:540-5.
Roxburgh R, Seaman S, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
Vickaryous N, Jitlal M, Jacobs BM, et al. Remote testing of vitamin D levels across the UK MS population—A case control study. PLOS One 2020;15:e0241459.
Simpson Jr S, Taylor B, Blizzard L, et al. Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193-203.
Fitzgerald KC, Munger KL, Köchert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol 2015;72:1458-65.
Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Multiple Sclerosis J 2015;21:1013-24.
Yu S, Li X, Yu F, et al. New evidence for associations between vitamin D receptor polymorphism and obesity: case-control and family-based studies. J Human Genetics 2020;65:281-5.
Levin GP, Robinson-Cohen C, De Boer IH, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012;308:1898-905.

How to Cite

Milanifard, M., Mehrabi, S., Ahadi, R., Nabiuni, M., Souteh , S. A., & Joghataei, M. T. (2024). Evaluation relationship between VDR gene and clinical and inflammatory factors in patients with RRMS. European Journal of Translational Myology. https://doi.org/10.4081/ejtm.2024.12939
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.